A lack of raw materials used in the manufacture of Pfizer’s COVID-19 vaccine played a role in the company’s decision to slash its 2020 production target, a spokeswoman told Reuters.
A lack of raw materials used in the manufacture of Pfizer’s COVID-19 vaccine played a role in the company’s decision to slash its 2020 production target, a spokeswoman told Reuters.